BMY

Bristol-Myers Squibb Co.

New York Stock Exchange

$60.53

Open: $60.91 High: $61.38 Low: $60.155 Close: $60.535

Range: 2021-09-20 - 2021-09-21

Volume:16,235,733

Market: Open

Get Free API Key

Download as Excel

BMY

Bristol-Myers Squibb Co. 345 Park Avenue New York NY, 10154 http://www.bms.com

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

CEO: Giovanni Caforio
Employees: 23,700
Sector: Healthcare
Industry: Drug Manufacturers

Latest Stocks Posts

View All Posts >

BMY News

Latest news about the BMY

Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
View More →
Bristol Myers Squibb (BMY) Stock Moves -1.32%: What You Should Know
Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.
View More →
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
View More →
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
PRINCETON, N.J., September 20, 2021--U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination...
View More →
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
When a biotech company develops a drug candidate that can help millions of people fight a monstrous disease such as Alzheimer's, it will certainly gain attention from scientists, the news media, and the U.S. Food and Drug Administration. For Prothena (NASDAQ: PRTA), a huge wave of attention has also come from investors since the start of the year. Or is this just a sign of more gains to come as it develops a potentially best-in-class Alzheimer's disease portfolio to enter a market projected to grow by 5.4% per year through 2026, to reach $9 billion?
View More →
Gritstone Unveils "Off-The-Shelf" Neoantigen Immunotherapy Data In Lung Cancer
Gritstone bio Inc (NASDAQ: GRTS) has announced results with its SLATE v1 product ("off-the-shelf" shared neoantigen immunotherapy). The therapy is in combination with Bristol-Myers Squibb Co's (NYSE: BMY) intravenous Opdivo (nivolumab) and subcutaneous Yervoy (ipilimumab). The Company has also dosed the first patient in Phase 2 trial of the optimized SLATE v2 product. SLATE v2 has been engineered to drive a more potent immune response to mutant KRAS neoantigens than were observed with SLATE v1.
View More →
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5
PRINCETON, N.J., September 17, 2021--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....
View More →
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.
View More →
Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy
Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Data were presented at the European Society for Medical Oncology Virtual Congress 2021 (ESMO21). Related Link: Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting. The Phase 3 CheckMate-214 trial showed a five-year survival rate of 48% and 37% for those receivi
View More →
Bristol Myers stock falls toward 6-month low, set to suffer longest losing streak in 3 1/2 years
Shares of Bristol Myers Squibb Co. slumped 1.7% in midday trading Thursday toward a six-month low, putting them on track to suffer the longest losing streak in 3 1/2 years. The stock is headed for a ninth-straight loss, and has declined 7.8% during that stretch. The last time it suffered a losing streak that long was the nine-day stretch ended April 23, 2018, when the stock fell 8.8%, according to data compiled by Dow Jones Market Data. The selloff comes as Congress is working on the infrastruct
View More →
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless of prior nephrectomy (surgical removal of a kidney) status. Data were shared at the 2021 European Society for Medical Oncology Congress (ESMO21). The Phase 3 CheckMate-9ER evaluated Cabometyx combined with Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) versus Pfizer Inc's (NYSE: PFE) Sutent
View More →
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
PRINCETON, N.J., September 16, 2021--Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial.....
View More →
Investing in These 2 Top Stocks Could Make You Richer Over the Next 10 Years
It's possible to get rich quickly by investing in stocks, but it isn't very likely to happen. One key factor to consider before putting your hard-earned money into any company is whether it benefits from a competitive edge. Two stocks that I believe have what it takes are Bristol Myers Squibb (NYSE: BMY) and Shopify (NYSE: SHOP).
View More →
Bristol-Myers Squibb's (NYSE:BMY) Profits are Understated and the Company has Room for New Growth
The market for Bristol-Myers Squibb Company's (NYSE:BMY) shares didn't move much after it posted weak earnings recently, but seems to be currently entering a bear run. When faced with uncertainty, it is always good to return to the fundamentals and see the performance and future growth capabilities of the company.
View More →
Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting
Bristol Myers Squibb & Co (NYSE: BMY) announced three-year data from the CheckMate -743 trial demonstrating a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemo in unresectable malignant pleural mesothelioma (MPM). Among patients treated with Opdivo plus Yervoy, 23% were alive at three years, compared to 15% treated with chemotherapy. Treatment with the dual immunotherapy combination continued to show a reduction in the risk of d
View More →
10 Best Value Dividend Stocks to Buy Now
In this article, we will be taking a look at the 10 best value dividend stocks to buy now. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Best Value Dividend Stocks to Buy Now. Value investing, the investment strategy pioneered by American economist Benjamin Graham, and religiously […]
View More →
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
PRINCETON, N.J., September 13, 2021--According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment...
View More →
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial
PRINCETON, N.J., September 13, 2021--Opdivo + Yervoy Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural....
View More →
Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA class) and Mortality in Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J., September 11, 2021--BMS Shares Research Supporting Correlation between NYHA class and Mortality in Obstructive Hypertrophic Cardiomyopathy
View More →
Bristol Myers Squibb (BMY) Stock Moves -0.71%: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $63.13, marking a -0.71% move from the previous day.
View More →

BMY

BMY

Bristol-Myers Squibb Co. 345 Park Avenue New York NY, 10154 http://www.bms.com

Latest Stocks Posts

View All Posts >

BMY News

Latest news about the BMY

Request a consultation.

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader

BMY

BMY

Bristol-Myers Squibb Co. 345 Park Avenue New York NY, 10154 http://www.bms.com

Share BMY Stock Page

Latest Stocks Posts

View All Posts >

BMY News

Latest news about the BMY

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader